LFM-A13, CAS 62004-35-7

Product Description: LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

Applications: Cancer-Kinase/protease

Formula: C11H8Br2N2O2

References: [1]Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99./[2] van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13./[3]Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14./[4]Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2018 Jun;36(3):388-395.

CAS Number: 62004-35-7

Molecular Weight: 360.00

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Btk;JAK;Polo-like Kinase (PLK)

• Artikelnummer: MEXHY-110002-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-110002-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK